TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Staar Surgical ( (STAA) ) is now available.
On December 9, 2025, STAAR Surgical Company announced an amendment to its merger agreement with Alcon Research, LLC, increasing the cash consideration for its common stock from $28.00 to $30.75 per share. The amendment also outlines the conversion of restricted stock units to Alcon shares and the elimination of certain tax indemnification arrangements, potentially enhancing shareholder value and streamlining the merger process.
The most recent analyst rating on (STAA) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
Staar Surgical’s overall stock score reflects significant financial and operational challenges, with negative profitability and liquidity issues being the most impactful factors. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable. The proposed merger with Alcon provides a potential positive catalyst, but legal uncertainties cloud the outlook.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company operates in the medical device industry, focusing on the development and commercialization of implantable lenses for the eye. The company is known for its innovative products aimed at improving vision and is a key player in the ophthalmic market.
Average Trading Volume: 945,672
Technical Sentiment Signal: Sell
Current Market Cap: $1.26B
See more insights into STAA stock on TipRanks’ Stock Analysis page.